Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-04-23
1999-12-07
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514 36, 514253, 514254, 514256, 514324, 514337, 514414, 514422, 514453, 544229, 544335, 544375, 546 14, 546 19, 5462801, 548110, 548467, 548525, 549 4, 549 25, 549383, A61K 3135, A61K 3138, C07D31178, C07D31194, C07D33504
Patent
active
059984643
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention provides novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action rely on the inhibition of 5.alpha.-reductase.
BACKGROUND OF THE INVENTION
Certain undesirable physiological manifestations, such as acne vulgaris, seborrhea, female hirsutism, androgenic alopecia which includes female and male pattern baldness, and benign prostatic hyperplasia, are the result of hyperandrogenic stimulation caused by excessive accumulation of testosterone ("T") or similar androgenic hormones in the metabolic system. Androgenic alopecia is also known as androgenetic alopecia. Early attempts to provide a chemotherapeutic agent to counter the undesirable results of hyperandrogenicity resulted in the discovery of several steroidal antiandrogens having undesirable hormonal activities of their own. The estrogens, for example, not only counteract the effect of the androgens but have a feminizing effect as well. Non-steroidal antiandrogens have also been developed, for example, 4'-nitro-3'-trifluoromethyl-isobutyranilide. See Neri, et al., Endocrinol. 1972, 91 (2). However, these products, though devoid of hormonal effects, compete with all natural androgens for receptor sites, and hence have a tendency to feminize a male host or the male fetus of a female host and/or initiate feed-back effects which would cause hyperstimulation of the testes.
The principal mediator of androgenic activity in some target organs, e.g. the prostate, is 5.alpha.-dihydrotestosterone ("DHT"), formed locally in the target organ by the action of testosterone-5.alpha.-reductase. Inhibitors of testosterone-5.alpha.-reductase will serve to prevent or lessen symptoms of hyperandrogenic stimulation in these organs. See especially U.S. Pat. No. 4,377,584, issued Mar. 22, 1983, and U.S. Pat. No. 4,760,071, issued Jul. 26, 1988, both assigned to Merck & Co., Inc.
The enzyme 5.alpha.-reductase catalyzes the reduction of testosterone to the more potent androgen, dihydrotestosterone, as shown below: ##STR2##
Finasteride, (17.beta.-(N-tert-butylcarbamoyl)-3-oxo-4-aza-5.alpha.-androst-1-ene-3-one ) as shown below, is a potent inhibitor of the human prostate enzyme. ##STR3## Under the trade name PROSCAR.RTM., finasteride is known to be useful in the treatment of hyperandrogenic conditions; see eg. U.S. Pat. No. 4,760,071. Finasteride is currently prescribed for the treatment of benign prostatic hyperplasia (BPH), a condition afflicting to some degree the majority of men over age 55. Finasteride's utility in the treatment of androgenic alopecia and prostatic carcinoma is also disclosed in the following documents: EP 0 285,382, published Oct. 5, 1988; EP 0 285,383, published Oct. 5, 1988; Canadian Patent no. 1,302,277; and Canadian Patent no. 1,302,276.
There are two isozymes of 5.alpha.-reductase in humans. One isozyme (type 1 or 5.alpha.-reductase 1) predominates in sebaceous glands of facial and skin tissue and is relatively insensitive to finasteride (see, e.g., G. Harris, et al., Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 10787-10791 (November 1992)); the other (type 2 or 5.alpha.-reductase 2) predominates in the prostate and is potently inhibited by finasteride.
Since 5.alpha.-reductase and its isozymes convert testosterone to DHT, inhibition of either or both of the isozymes would serve to alleviate the conditions and diseases mediated by DHT. The present invention addresses this by providing novel compounds that are active as inhibitors of 5.alpha.-reductase.
SUMMARY OF THE INVENTION
The novel compounds of the present invention are those of structural formula I: ##STR4## wherein X is selected from O and S, or a pharmaceutically acceptable salt, ester, or stereoisomer thereof, and are inhibitors of 5.alpha.-reductase. The compounds of formula I are useful in the oral, systemic, parenteral or topical treatment of hyperandrogenic conditions such as acne vulgaris, seborrhea, andr
REFERENCES:
patent: 3644421 (1972-02-01), Cross
patent: 4760071 (1988-07-01), Rasmusson et al.
patent: 5075450 (1991-12-01), Rasmusson et al.
patent: 5084574 (1992-01-01), Bhattacharya et al.
patent: 5091380 (1992-02-01), Rasmusson et al.
Wall Street Journal, May 7, 1996, p. B4, "Study finds Abbott's prostate drug is much more effective than Merck's ".
The Daily, Tuesday, May 7, 1996, "New data on Proscar, Abbott's Hytrin show conflicting results".
Tian et al., Biochemistry, vol. 33 (1994), pp. 2291-2296, "17beta-(N-tert-butylcarbmoyl)-4-aza-5alpha-androstan-1-en-3-one is an active site-directed slow time-dependent . . . ".
Everse et al., Bioorganic Chemistry, vol. 1 (1971), pp. 207-233, "Addition products of diphosphopyridine nucleotides with substracts of pyridine nucleotide-linked dehydrogenases".
Bull et al., J. Am. Chem. Soc., vol. 118 (1996), pp. 2359-2365, "Mechanism-based inhibition of human steroid 5alpha-reductase by finasteride".
Faller et al., Biochemistry, vol. 32 (1993), pp. 5705-5710, "Finasteride: A slow-binding 5alpha-reductase inhibitor".
Baginsky et al., FASEB J., vol. 8 (1994), p. 638, "Mechanism of inhibition of human prostatic 5alpha-reductase by 4-azasteroids".
Barton et al., J. of the Chem. Soc., Perkin Trans. 1, No. 8 (1982), pp. 1919-1922, "Dehydrogenation of lactones using benzeneseleninic ahydride".
Barton et al., Tetrahedron Letters, No. 35 (1979), pp. 3331-3334, "Preparation of aldehydes and ketones by oxidation of benzylic hydrocarbons with benzeneseleninic anhydride".
Canovas et al., Helv. Chmi. Acta., vol. 63(8), pp. 2390-2392 (1980), "253. A Norrish Type I cleavage in the photolysis of a steroidal alpha, beta-unsaturated gamma-lactone".
Caspi et al., Tetrahedron, vol. 18, pp. 1013-1018 (1962), "Ozonolysis of conjugated systems-II . . . ".
Bakshi Raman K.
Patel Gool F.
Rasmusson Gary H.
Tolman Richard L.
Coleman Brenda
Fitch Catherine D.
Merck & Co. , Inc.
Raymond Richard L.
Winokur Melvin
LandOfFree
4-Oxa and 4-thia steroids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-Oxa and 4-thia steroids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-Oxa and 4-thia steroids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-824489